Rosiglitazone (BRL 49653): Mechanism of Action

Rosiglitazone (BRL 49653) MOA:Targeting PPARγ/Insulin Signaling Pathway for Type 2 Diabetes and Metabolic Syndrome

🎯 check Rosiglitazone (BRL 49653) product page

Rosiglitazone (BRL 49653) is a potent, highly selective PPARγ agonist. It affects PPAR and insulin signaling pathways by binding to the receptor's ligand-binding domain to regulate target gene transcription, effectively promoting adipocyte differentiation and improving systemic insulin sensitivity.

Primary Applications and Mechanism of Action